These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 21915392)
21. Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. Zhou H; Li SH; Li XJ J Biol Chem; 2001 Dec; 276(51):48417-24. PubMed ID: 11606565 [TBL] [Abstract][Full Text] [Related]
22. Huntingtin aggregation and toxicity in Huntington's disease. Bates G Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895 [TBL] [Abstract][Full Text] [Related]
23. Overexpression of F(0)F(1)-ATP synthase alpha suppresses mutant huntingtin aggregation and toxicity in vitro. Wang HQ; Xu YX; Zhao XY; Zhao H; Yan J; Sun XB; Guo JC; Zhu CQ Biochem Biophys Res Commun; 2009 Dec; 390(4):1294-8. PubMed ID: 19878659 [TBL] [Abstract][Full Text] [Related]
24. Assessing Autophagic Activity and Aggregate Formation of Mutant Huntingtin in Mammalian Cells. Stamatakou E; Zhu Y; Rubinsztein DC Methods Mol Biol; 2018; 1780():17-29. PubMed ID: 29856012 [TBL] [Abstract][Full Text] [Related]
25. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset. Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262 [TBL] [Abstract][Full Text] [Related]
26. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease. Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099 [TBL] [Abstract][Full Text] [Related]
27. Huntingtin exon 1 fibrils feature an interdigitated β-hairpin-based polyglutamine core. Hoop CL; Lin HK; Kar K; Magyarfalvi G; Lamley JM; Boatz JC; Mandal A; Lewandowski JR; Wetzel R; van der Wel PC Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1546-51. PubMed ID: 26831073 [TBL] [Abstract][Full Text] [Related]
28. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Brehme M; Voisine C; Rolland T; Wachi S; Soper JH; Zhu Y; Orton K; Villella A; Garza D; Vidal M; Ge H; Morimoto RI Cell Rep; 2014 Nov; 9(3):1135-50. PubMed ID: 25437566 [TBL] [Abstract][Full Text] [Related]
29. Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms. Chen X; Burgoyne RD BMC Genomics; 2012 Feb; 13():71. PubMed ID: 22333271 [TBL] [Abstract][Full Text] [Related]
30. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Truant R; Atwal RS; Burtnik A Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517 [TBL] [Abstract][Full Text] [Related]
31. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Lee WC; Yoshihara M; Littleton JT Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262 [TBL] [Abstract][Full Text] [Related]
32. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219 [TBL] [Abstract][Full Text] [Related]
33. Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models. Tauffenberger A; Chitramuthu BP; Bateman A; Bennett HP; Parker JA Hum Mol Genet; 2013 Feb; 22(4):782-94. PubMed ID: 23172908 [TBL] [Abstract][Full Text] [Related]
35. Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. Juenemann K; Weisse C; Reichmann D; Kaether C; Calkhoven CF; Schilling G Neurotox Res; 2011 Aug; 20(2):120-33. PubMed ID: 21116768 [TBL] [Abstract][Full Text] [Related]
36. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Williams A; Jahreiss L; Sarkar S; Saiki S; Menzies FM; Ravikumar B; Rubinsztein DC Curr Top Dev Biol; 2006; 76():89-101. PubMed ID: 17118264 [TBL] [Abstract][Full Text] [Related]
37. Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders. Weydt P; La Spada AR Expert Opin Ther Targets; 2006 Aug; 10(4):505-13. PubMed ID: 16848688 [TBL] [Abstract][Full Text] [Related]
38. Nucleic Acid Therapeutics in Huntington's Disease. Singh K; Roy I Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088 [TBL] [Abstract][Full Text] [Related]
39. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model. van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347 [TBL] [Abstract][Full Text] [Related]